|Security||SGNT / Sagent Pharmaceuticals, Inc. (786692103)|
|Common Shares Outstanding||32,910,475 shares (as of 2016-06-30)|
Institutional Stock Ownership and Shareholders
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) has 0 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
Largest shareholders include
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Related News Stories
Despite having risen nearly 50% from 2017 lows of $2, PDLI biopharma (PDLI) remains undervalued, and activist investors are starting to notice. Recent activist behavior from SevenSaoi Capital could act as yet another catalyst for PDL’s price to increase towards book value of $5.84, nearly 110% higher than the current price of $2.9. (200-3)
as of ET